6-(piperidin-1-yl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine | 312617-36-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并哒嗪类
• 英文名称: 6-(piperidin-1-yl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine
• 英文别名: 6-(1-Piperidinyl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine；6-piperidin-1-yl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine
• CAS: 312617-36-0
• 化学式: C₁₁H₁₂F₃N₅
• 分子量: 271.245
• InChiKey: OIIAVBIQRXMPKJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  46.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  哌啶 、 6-氯-3-(三氟甲基)[1,2,4]噻唑并[4,3-b]吡嗪 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 以65%的产率得到6-(piperidin-1-yl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine
  参考文献：
  名称：

  Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

  摘要：

  Chemical starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer. Although prototypic steroidal downregulators such as 6a designed for intramuscular administration showed insufficient cellular potency, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]3-(trifluoromethyl)[1,2,4] triazolo[4,3-b] pyridazine (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.122

文献信息

• Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
  作者：Robert H. Bradbury、Neil J. Hales、Alfred A. Rabow、Graeme E. Walker、David G. Acton、David M. Andrews、Peter Ballard、Nigel A.N. Brooks、Nicola Colclough、Alan Girdwood、Urs J. Hancox、Owen Jones、David Jude、Sarah A. Loddick、Andrew A. Mortlock

  DOI：10.1016/j.bmcl.2011.06.122

  日期：2011.9

  Chemical starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer. Although prototypic steroidal downregulators such as 6a designed for intramuscular administration showed insufficient cellular potency, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]3-(trifluoromethyl)[1,2,4] triazolo[4,3-b] pyridazine (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency. (C) 2011 Elsevier Ltd. All rights reserved.